| Document And Entity Information | Apr. 04, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Apr. 4, 2022 |
| Entity Registrant Name | Inozyme Pharma, Inc. |
| Entity Central Index Key | 0001693011 |
| Entity Emerging Growth Company | true |
| Entity File Number | 001-39397 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 38-4024528 |
| Entity Address, Address Line One | 321 Summer Street |
| Entity Address, Address Line Two | Suite 400 |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 0221 |
| City Area Code | 857 |
| Local Phone Number | 330-4340 |
| Entity Information, Former Legal or Registered Name | Not applicable |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | false |
| Title of 12(b) Security | Common stock, par value $0.0001 per share |
| Trading Symbol | INZY |
| Security Exchange Name | NASDAQ |
